Axa S.A. Purchases 4,715 Shares of Penumbra, Inc. $PEN

Axa S.A. grew its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 4.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 105,870 shares of the company’s stock after buying an additional 4,715 shares during the period. Axa S.A.’s holdings in Penumbra were worth $27,169,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PEN. GAMMA Investing LLC boosted its stake in Penumbra by 7.3% during the second quarter. GAMMA Investing LLC now owns 761 shares of the company’s stock worth $195,000 after acquiring an additional 52 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Penumbra by 70.2% during the second quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after purchasing an additional 66 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Penumbra by 2.9% in the 2nd quarter. Quadrant Capital Group LLC now owns 2,872 shares of the company’s stock worth $737,000 after purchasing an additional 82 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Penumbra by 0.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 10,900 shares of the company’s stock worth $2,797,000 after buying an additional 100 shares during the last quarter. Finally, New York State Teachers Retirement System grew its stake in shares of Penumbra by 0.3% in the 2nd quarter. New York State Teachers Retirement System now owns 38,154 shares of the company’s stock worth $9,791,000 after buying an additional 100 shares during the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Penumbra news, EVP Johanna Roberts sold 300 shares of Penumbra stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $300.13, for a total transaction of $90,039.00. Following the transaction, the executive vice president owned 63,836 shares of the company’s stock, valued at $19,159,098.68. The trade was a 0.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arani Bose sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $300.19, for a total transaction of $2,251,425.00. Following the completion of the transaction, the director owned 275,261 shares of the company’s stock, valued at approximately $82,630,599.59. The trade was a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 19,744 shares of company stock worth $5,755,174. Company insiders own 4.20% of the company’s stock.

Penumbra Trading Up 5.5%

NYSE:PEN opened at $302.89 on Thursday. Penumbra, Inc. has a one year low of $221.26 and a one year high of $310.00. The business has a fifty day moving average price of $266.75 and a 200-day moving average price of $258.56. The firm has a market capitalization of $11.86 billion, a price-to-earnings ratio of 72.46, a price-to-earnings-growth ratio of 2.37 and a beta of 0.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.07. The company had revenue of $354.69 million for the quarter, compared to the consensus estimate of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.Penumbra’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.85 earnings per share. Sell-side analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PEN shares. Wall Street Zen cut shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Evercore ISI reissued an “outperform” rating and issued a $286.00 target price on shares of Penumbra in a research report on Thursday, November 6th. BTIG Research restated a “buy” rating and set a $320.00 target price on shares of Penumbra in a research note on Monday, October 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a report on Monday. Finally, Canaccord Genuity Group boosted their price objective on shares of Penumbra from $350.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $305.69.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.